Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal

C R Biol. 2013 May-Jun;336(5-6):295-300. doi: 10.1016/j.crvi.2013.04.016. Epub 2013 Jul 18.

Abstract

Senegal has since 2003 used sulphadoxine-pyrimethamine (SP) for Intermittent Preventive Treatment (IPT) of malaria in risk groups. However, the large-scale IPT strategy may result in increasing drug resistance. Our study investigated the possible impact of SP-IPT given to infants and children on the prevalence of SP-resistant haplotypes in the Plasmodium falciparum genes Pfdhfr and Pfdhps, comparing sites with and without IPTi/c. P. falciparum positives samples (n=352) were collected from children under 5years of age during two cross-sectional surveys in 2010 and 2011 in three health districts (two on IPTi/c and one without IPTi/c intervention) located in the southern part of Senegal. The prevalence of SP-resistance-related haplotypes in Pfdhfr and Pfdhps was determined by nested PCR followed by sequence-specific oligonucleotide probe (SSOP)-ELISA. The prevalence of the Pfdhfr double mutant haplotypes (CNRN and CICN) was stable between years at<10% in the control group (P=0.69), while it rose significantly in the IPTi/c group from 2% in 2010 to 20% in 2011 (P=0.008). The prevalence of the Pfdhfr triple mutant haplotype (CIRN) increased in both groups, but only significantly in the IPTi/c group from 41% to 65% in 2011 (P=0.005). Conversely, the Pfdhps 437G mutation decreased in both groups from 44.6% to 28.6% (P=0.07) and from 66.7% to 47.5% (P=0.02) between 2010 and 2011 in the control and the IPTi/c groups, respectively. Combined with Pfdhfr, there was a weak trend for decreasing prevalence of quadruple mutants (triple Pfdhfr+Pfdhps 437G) in both groups (P=0.15 and P=0.34). During the two cross-sectional surveys, some significant changes were observed in the SP-resistance-related genes. However, since these changes were observed in the two groups, the IPTi/c strategy does only seem to have limited impact on resistance development and other factors as well. However, continuous monitoring will be needed, due to the up-scaling of the IPTi/c strategy in Senegal according to WHO recommendations.

Keywords: Children; Enfants; Malaria; Mutation; P. falciparum; Senegal; Sulphadoxine-pyrimethamine; Sénégal.

MeSH terms

  • Animals
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use*
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • DEAD-box RNA Helicases / genetics
  • DNA Helicases / genetics
  • DNA, Protozoan / genetics
  • Drug Combinations
  • Drug Resistance*
  • Female
  • Haplotypes
  • Humans
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / parasitology
  • Male
  • Plasmodium falciparum / drug effects*
  • Polymorphism, Single Nucleotide
  • Prevalence
  • Pyrimethamine / pharmacology
  • Pyrimethamine / therapeutic use*
  • Senegal / epidemiology
  • Sulfadoxine / pharmacology
  • Sulfadoxine / therapeutic use*
  • Time Factors

Substances

  • Antimalarials
  • DNA, Protozoan
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • DNA Helicases
  • DEAD-box RNA Helicases
  • DH60 protein, Plasmodium falciparum
  • Pyrimethamine